



Microbiological quality, chemical profile as well as antioxidant and antidiabetic activities of *Schinus terebinthifolius* Raddi

Paola dos Santos da Rocha^a, Ana Paula de Araújo Boleti^a, Maria do Carmo Vieira^b, Carlos Alexandre Carollo^c, Denise Brentan da Silva^c, Leticia Miranda Estevinho^d, Edson Lucas dos Santos^a, Kely de Picoli Souza^{a,*}

^a Research group on Biotechnology and Bioprospecting Applied to Metabolism, Federal University of Grande Dourados, Rodovia Dourados Itahum, Km 12, 79804-970 Dourados, MS, Brazil

^b Agricultural Sciences, Federal University of Grande Dourados, Rodovia Dourados-Itahum, Km 12, Brazil

^c Laboratory of Natural Products and Mass Spectrometry, Federal University of Mato Grosso do Sul, Cidade Universitária, 79070-900 Campo Grande, MS, Brazil

^d Polytechnic Institute of Bragança, Agricultural College of Bragança, Campus Santa Apolónia, 5301-855 Bragança, Portugal

ARTICLE INFO

Keywords:

Brazilian peppertree
Safety
Phenolic compounds
Oxidative stress
Glycemic control
Diabetes

ABSTRACT

Schinus terebinthifolius Raddi, commonly known as Brazilian peppertree, is a plant species widely used in Brazilian traditional medicine for various purposes. The objective of this study was to assess the microbiological quality, safety, chemical profile as well as antioxidant and antidiabetic potentials of different parts of *S. terebinthifolius*. Microbiological analysis of the methanolic extracts of the roots (MESR), stem bark (MESB) and leaves (MESL) of *S. terebinthifolius* showed no microbial growth. The concentrations of phenolic compounds, phenolic acids and flavonoids were determined by spectrophotometry. The phenolic compounds of the MESL were identified by liquid chromatography coupled to a diode array detector and mass spectrometer (LC-DAD-MS). The antioxidant activities of the extracts were analyzed by 2,2-diphenyl-1-(2,4,6-trinitrophenyl)hydrazyl radical (DPPH·), 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) radical (ABTS·⁺), fluorescence recovery after photobleaching (FRAP), reducing power, β-carotene bleaching and malondialdehyde (MDA) assays in human erythrocytes. The antidiabetic properties of the extracts were demonstrated *in vitro* by their inhibition of the α-glucosidase enzyme and their anti-glycation activity *via* fructose and glyoxal. After showing no acute toxicity *in vivo*, MESL was able to lower postprandial glycemia after glucose overload in normoglycemic mice as well as the water and feed intake, liver weight, glycemia and serum levels of glycated hemoglobin, aspartate transaminase (AST) and alanine transaminase (ALT) in diabetic mice. Overall, *S. terebinthifolius* extracts showed microbiological safety along with antioxidant and antidiabetic activities, likely mediated by its chemical constituents, such as gallic acid, gallotannins and glycosylated flavonols.

1. Introduction

Schinus terebinthifolius Raddi, belonging to the Anacardiaceae family, is a medicinal plant native to Brazil, commonly known as aroeira or Brazilian peppertree. Previous studies have shown that *S. terebinthifolius* contains phenolic compounds with different biological activities, as described below. In traditional medicine, this plant is used to treat skin wounds and ulcers, tumors, diarrhea, arthritis as well as urinary and respiratory tract infections (Brandão et al., 2006). Various pharmacological activities have been described for this plant, including antimicrobial (Silva et al., 2017a), antiulcerogenic (Carlini et al., 2010), anticancer (Silva et al., 2017b), antihistamine (Nunes-Neto et al.,

2017), antihypertensive (Glória et al., 2017), antihyperalgesic (Piccinelli et al., 2015), wound healing (Estevão et al., 2017), anti-inflammatory (Silva et al., 2017b) and antioxidant (Rocha et al., 2017) activities in different models.

The increasing use of medicinal plants and/or natural products highlights the need for studies on their efficacy and safety. Among the main factors affecting these characteristics of natural products, their microbiological quality stands out because the presence and quantity of some species of microorganisms in the raw material may directly affect the biological activity of the final product (Ratajczak et al., 2015). The microbiological analysis of medicinal plants and/or non-sterile pharmaceutical products aims to identify and quantify the microbial content

* Corresponding author.

E-mail address: kelypicoli@gmail.com (K. de Picoli Souza).

<https://doi.org/10.1016/j.cbpc.2019.02.007>

Received 7 December 2018; Received in revised form 14 February 2019; Accepted 15 February 2019

Available online 21 February 2019

1532-0456/ © 2019 Elsevier Inc. All rights reserved.

for ensuring the quality and safety of these products for human health (Ratajczak et al., 2015).

Diabetes mellitus is among the diseases currently considered to be a global epidemic, projected to grow among the world population and for which new therapeutic alternatives are constantly sought (Wild et al., 2004; Kharroubi and Darwish, 2015). It is a multifactorial disease characterized by the development of metabolic disorders initially involving the elevation of glycemia in response to poor insulin secretion (type 1 diabetes) or cellular resistance to this hormone (type 2 diabetes) (Kharroubi and Darwish, 2015).

Prolonged exposure to hyperglycemia is directly related to increased levels of free radicals, which trigger or aggravate oxidative stress. In combination, these changes lead to structural and functional abnormalities of the endothelium and other tissues, thus contributing to the development of cardiovascular diseases and other comorbidities in diabetics (Node and Inoue, 2009; Singh et al., 2014; Kharroubi and Darwish, 2015). Diabetic complications are aggravated by factors such as postprandial hyperglycemia and the formation of advanced glycation end products (AGEs) (Node and Inoue, 2009; Singh et al., 2014). Thus, medicinal plants with antioxidant and antihyperglycemic properties have become alternatives in the treatment of diabetes.

In this context, the objectives of this study were to determine the quality and safety; identify the phytochemical constituents; and assess the *in vitro* as well as *in vivo* antioxidant and antidiabetic properties of different parts of *S. terebinthifolius*.

2. Material and methods

2.1. Plant material and extract preparation

The roots, stem bark and leaves of *Schinus terebinthifolius* Raddi were collected after authorization from the SISBIO (*Sistema de Autorização e Informação em Biodiversidade*; permit number 45365-1). The plant material was collected in Dourados, Mato Grosso do Sul, Brazil, at geographic coordinates 22°11'43.7568" S and 54°56'8.0916" W. A voucher specimen was deposited in the herbarium of the Federal University of Grande Dourados, UFGD, Brazil (DDMS number 4889). The plant materials were dried in an air circulation oven at 30 °C ± 5 °C days, pulverized in a knife mill and then maintained under intensive maceration in methanol P.A (99.8%). The filtrate was concentrated under vacuum on a rotary evaporator at 45 °C and then lyophilized. The yields of the methanolic extracts were approximately 2% for the roots (MESR), 7% for the stem bark (MESB) and 13% for the leaves (MESL) of *S. terebinthifolius*.

2.2. Microbiological analysis

To assess the microorganisms, 5 g of powder or 1 g of extract was aseptically weighed and homogenized with 45 or 9 mL of 0.5% sterile peptone solution, respectively. Serial dilutions (1:10) of the sample were prepared using the homogenate in the same sterile diluent. Two independent assays were performed in duplicate, as described below.

2.2.1. Total mesophilic and psychrophilic microorganisms

Total mesophilic and psychrophilic microorganisms were quantified according to NP-3788 (2002). Sample dilutions were incorporated (1 mL) into or plated (0.1 mL) in plate count agar (PCA) media in Petri dishes. Colonies were counted after incubation in the Petri dishes at 30 °C for 72 h and at 15 °C for 5 days. The results were expressed as colony forming units (CFU/g).

2.2.2. Molds and yeasts

Molds and yeasts were counted in DG18 growth media. Sample dilutions (0.1 mL) were plated and incubated at 25 °C for 5 days according to ISO-21527-2 (2008). The microbial counts were expressed as CFU/g.

2.2.3. Sulfite-reducing *Clostridium* sp. spores

Sulfite-reducing *Clostridium* sp. spores were quantified according to ISO-15213 (2003). For this purpose, sample dilutions were heated to 80 °C for 10 min. Subsequently, 1 mL sample dilutions were added to tubes containing iron sulfite agar. Then, another layer of agar was added. After the media solidified, the tubes were incubated at 37 °C for 5 days. The formation of black colonies in test tubes was considered a positive result. The results were expressed as CFU/g.

2.2.4. *Salmonella* sp

Salmonella sp. was detected using the immunodiffusion 1–2 test, as described by the AOAC (1989). The results were obtained after pre-enriching the sample in sterile buffered peptone water (1:10) incubated at 37 °C for 24 h. The results were visually interpreted by monitoring the development of an immunoband.

2.2.5. *Escherichia coli*

Escherichia coli was quantified using the SimPlate® Total Plate Count BioControl kit according to the AOAC (2005). The culture medium supplied was rehydrated in 9 mL of distilled water, and the sample dilutions (1 mL) were inoculated according to the manufacturer's instructions. The content was poured onto 84-well plates. The plates were incubated at 37 °C for 24 h. *E. coli* was quantified by counting the number of wells in which fluorescence was observed after exposure to ultraviolet light at 365 nm. *E. coli* populations were defined based on the number of positive wells, correlating the results with the SimPlate conversion table and expressing them as CFU/g.

2.2.6. *Staphylococcus aureus*

To identify *O* (0.1 mL) were plated in Baird-Parker agar with egg yolk tellurite emulsion, as described in NP-4400-1 (2002), for 48 h at 37 °C. The results were expressed as CFU/g.

2.2.7. *Bacillus cereus*

Bacillus cereus was counted according to ISO-7932 (2004) using mannitol-egg yolk-polymyxin B agar (MYP). Sample dilutions (0.1 mL) were plated and incubated at 30 °C for 24 h. Typical *Bacillus cereus* colonies (with a dry and rough red-purple surface with a white precipitate) were counted, and the results were expressed as CFU/g.

2.3. Concentrations of phytochemical constituents

2.3.1. β -Carotene and lycopene

β -Carotene and lycopene were determined according to the method of Barros et al. (2007). The extract (150 mg) was vigorously shaken with 10 mL of an acetone–hexane mixture (4:6) for 1 min and filtered through Whatman No. 4 filter paper. The absorbance of the filtrate was measured at 453, 505 and 663 nm. The contents of β -carotene and lycopene were calculated according to the following equations: β -carotene = $0.216 \times A_{663} - 0.304 \times A_{505} + 0.452 \times A_{453}$; and lycopene = $-0.0458 \times A_{663} + 0.372 \times A_{505} - 0.0806 \times A_{453}$. The assays were carried out in triplicate. The results were expressed as the mean value ± standard deviation as mg of carotenoid/g of extract.

2.3.2. Ascorbic acid

The ascorbic acid was determined according to the method of Barros et al. (2007). The extract (100 mg) was extracted with 10 mL of 1% metaphosphoric acid for 45 min at room temperature and filtered through Whatman No. 4 filter paper. The filtrate (1 mL) was mixed with 9 mL of 2,6-dichlorophenolindophenol, and the absorbance was measured within 30 min at 515 nm. The content of ascorbic acid was calculated on the basis of the calibration curve of ascorbic acid (0.020–0.12 mg/mL). The assays were carried out in triplicate and expressed as mg of ascorbic acid/g of extract.

2.3.3. Phenolic compounds

The phenolic compounds were determined according to the method of Pinela et al. (2011). The extract concentrated at 0.625 mg/mL (250 μ L) was mixed with 0.1% HCl or 2% HCl (4550 μ L) in 95% ethanol (250 μ L). After 15 min, the absorbance was measured at 280, 320 and 360 nm. The absorbance at 280 nm was used to estimate the total phenolic content, while $A_{320\text{nm}}$ was used to determine the phenolic acids and $A_{360\text{nm}}$ was used to determine the flavonoids. Gallic acid was used to calculate the standard curve (50–500 μ g/mL), and the results were expressed as mg of gallic acid equivalents (GAE)/g of extract. Caffeic acid was used to calculate the standard curve (50–500 μ g/mL), and the results were expressed as mg of caffeic acid equivalents (CAE)/g of extract. Quercetin was used to calculate the standard curve (30–300 μ g/mL), and the results were expressed as mg of quercetin equivalents (QE)/g of extract. The assays were carried out in triplicate.

2.3.4. Identification of the constituents by LC-DAD-MS

The MESL was analyzed by an ultra-fast liquid chromatograph (Prominence, Shimadzu) coupled to a diode array detector (DAD) and mass spectrometer (MicrOTOF-Q III, Bruker Daltonics, Billerica, MA, USA). A Kinetex C18 column (2.6 μ m, 150 \times 2.1 mm, Phenomenex) was used with an injection volume, flow rate and oven temperature of 4 μ L, 0.3 mL/min and 50 $^{\circ}$ C, respectively. Acetonitrile (solvent B) and water (solvent A), both containing 0.1% formic acid, were applied as the mobile phase using the following gradient elution profile: 0–8 min at 3% B, 8–30 min at 8–25% B, 30–60 min at 25–80% B and 60–63 min at 80% B. For the mass spectrometry, nitrogen was used as the nebulizer gas (4 bar), dry gas (9 L/min) and collisional gas, and the capillary voltage was 2.5 kV. The extract was analyzed at a concentration of 1 mg/mL in the negative and positive ion modes.

2.4. Antioxidant activity

2.4.1. DPPH \cdot assay

The 2,2-diphenyl-1-picrylhydrazyl radical (DPPH \cdot) scavenging activity was evaluated according to the method described by Campos et al. (2014). For this experiment, 200 μ L of the extract was mixed with 1800 μ L of 0.11 mM DPPH \cdot solution in 80% ethanol. The final concentrations of the extract ranged from 0.1 to 1000 μ g/mL. The mixture was incubated at room temperature in the dark for 30 min. The absorbance was measured at 517 nm. Ascorbic acid and butylated hydroxytoluene (BHT) were used as reference antioxidants. As a control, 200 μ L of the solvent (80% ethanol) was incubated with 1800 μ L of the DPPH \cdot solution. Three independent experiments were performed in triplicate. The percent inhibition was calculated from the control using the following equation: capture activity of DPPH \cdot (%) = $(1 - \text{Abs}_{\text{sample}}/\text{Abs}_{\text{control}}) \times 100$. The concentrations of the extracts resulting in 50% inhibition (IC_{50}) were determined.

2.4.2. ABTS \cdot^+ assay

The 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) radical (ABTS \cdot^+) scavenging activity was evaluated according to the method described by Campos et al. (2015). For this experiment, the ABTS \cdot^+ was prepared from a mixture of 5 mL of ABTS (7 mM) and 88 μ L of potassium persulfate (140 mM), which was incubated for 12–16 h at room temperature in the dark. After this period, the ABTS \cdot^+ solution was diluted in absolute ethanol until an absorbance of 0.70 ± 0.05 was obtained at 734 nm. Then, 20 μ L of the extract was added to 1980 μ L of the ABTS \cdot^+ . The final concentrations of the extract ranged from 0.1 to 200 μ g/mL. The mixture was incubated at room temperature in the dark for 6 min. The absorbance was evaluated at 734 nm. Ascorbic acid and BHT were used as positive controls. As a control, 20 μ L of the solvent (80% ethanol) was incubated with 1980 μ L of ABTS \cdot^+ . Three independent experiments were performed in triplicate. The percentage of ABTS \cdot^+ inhibition was calculated according to the following equation: inhibition of ABTS \cdot^+ (%) = $(\text{Abs}_{\text{control}} - \text{Abs}_{\text{sample}})/\text{Abs}_{\text{control}} \times 100$.

The IC_{50} values were determined.

2.4.3. FRAP assay

The ferric reducing antioxidant power (FRAP) assay was evaluated according to the method described by Pulido et al. (2000). For this experiment, 100 μ L of extract (1–1000 μ g/mL) was mixed with 3 mL of FRAP reagent and 300 μ L of distilled water. The FRAP reagent contained 10 mL of 10 mmol/L 2,4,6-tri(2-pyridyl)-s-triazine (TPTZ) solution in 40 mmol/L HCl, 10 mL of 20 mmol/L $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ and 100 mL of 0.3 mol/L acetate buffer (pH = 3.6). The mixture was incubated at room temperature in the dark for 20 min. The absorbance was measured at 595 nm. Ascorbic acid was used as the reference antioxidant. As a control, 100 μ L of the solvent (80% ethanol) was incubated with 3 mL of FRAP reagent and 300 μ L of distilled water. Three independent experiments were performed in triplicate. The half maximal effective concentration (EC_{50}) value was determined using the corresponding regression equation.

2.4.4. Reducing power assay

The reducing power was evaluated according to the method described by Berker et al. (2007). For this experiment, 1 mL of extract (1–1000 μ g/mL) was combined with 2.5 mL of 0.2 M phosphate buffer (pH = 6.6) and 2.5 mL of $\text{K}_3\text{Fe}(\text{CN})_6$ solution (1%); the mixture was incubated at 50 $^{\circ}$ C in a water bath for 20 min. The incubated mixture was let cool to room temperature, and 2.5 mL of 2,4,6-trichloroanisole (TCA, 10%) was added. The solution was thoroughly mixed, an aliquot of 2.5 mL was withdrawn, and 2.5 mL of water followed by 0.5 mL of $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ solution (0.1%) was added so that the final volume was 5.5 mL. The absorbance was measured at 700 nm after 2 min. Ascorbic acid was used as the reference antioxidant. As a control, 1 mL of the solvent (80% ethanol) was combined with 2.5 mL of 0.2 M phosphate buffer (pH = 6.6) and 2.5 mL of $\text{K}_3\text{Fe}(\text{CN})_6$ solution (1%); the mixture was incubated at 50 $^{\circ}$ C in a water bath for 20 min. The incubated mixture was cooled to room temperature, and 2.5 mL of TCA (10%) was added. The solution was thoroughly mixed, an aliquot of 2.5 mL was withdrawn, and 2.5 mL of water followed by 0.5 mL of $\text{FeCl}_3 \cdot 6\text{H}_2\text{O}$ solution (0.1%) were added so that the final volume was 5.5 mL. Three independent experiments were performed in triplicate. The EC_{50} value was determined using the corresponding regression equation.

2.4.5. β -Carotene bleaching assay

β -Carotene bleaching inhibition was evaluated according to the method described by Taga et al. (1984). For this experiment, 2 mg of β -carotene was dissolved in 10 mL of chloroform. The absorbance was tested after adding 0.2 mL of the solution to 5 mL of chloroform and then reading the absorbance of this solution at 470 nm. A reading between 0.6 and 0.9 indicated a workable concentration of β -carotene. One milliliter of β -carotene chloroform solution was added with a pipette to a boiling flask that contained 20 mg of linoleic acid and 200 mg of Tween 40. Chloroform was removed using a rotary evaporator at 40 $^{\circ}$ C, and 50 mL of oxygenated distilled water was slowly added to the flask with vigorous agitation to form an emulsion. Five milliliters of the emulsion was added to 0.2 mL of the extract in spectrophotometer tubes. A blank consisting of 2 mg of linoleic acid, 20 mg of Tween 40 and 5 mL of oxygenated water was used to bring the spectrophotometer to zero. Tubes were shaken, and absorbance measurements made at 470 nm immediately after the addition of the emulsion to the extract as well as again after 60 min. The tubes were placed in an agitating water bath at 50 $^{\circ}$ C. The absorbance was measured at 470 nm. Butylated hydroxyanisole (BHA) was used as reference antioxidant. As a control, 200 μ L of the solvent (80% ethanol) was incubated with 5 mL of the emulsion. Three independent experiments were performed in triplicate. The percent inhibition was calculated from the control using the following equation: β -carotene bleaching inhibition (%) = $(1 - \text{Abs}_{\text{sample}}/\text{Abs}_{\text{control}}) \times 100$. The IC_{50} values were determined.

2.4.6. Dosage of malondialdehyde (MDA) assay

The antioxidant assay for the model of human erythrocytes was evaluated according to the method described by Rocha et al. (2017). Human erythrocyte assays were performed after receiving approval from the Research Ethics Committee (Comitê de Ética em Pesquisa, CEP) of the Federal University of Grande Dourados (Universidade Federal da Grande Dourados, UFGD), Brazil (CEP process number 1.739.987). Peripheral blood from healthy donors was collected and placed in tubes containing sodium citrate. The tubes were then centrifuged at $2000 \times g$ for 5 min, and the blood plasma as well as leukocyte layer were discarded. The erythrocytes were washed three times with 0.9% sodium chloride (NaCl) solution, and then, a 10% erythrocyte suspension in 0.9% NaCl solution was prepared for the assay.

The erythrocytes were pre-incubated at 37°C for 30 min with different concentrations of the extract (50–250 $\mu\text{g}/\text{mL}$). Ascorbic acid was used as a positive control. Then, 2,2'-azobis(2-amidinopropane) dihydrochloride (AAPH) solution (50 mM) was added, and the samples were incubated at 37°C for 180 min with periodic homogenization. After this time, the samples were centrifuged at $2000 \times g$ for 5 min, and 0.5 mL of the supernatant was mixed with 1 mL of 10 nmol thiobarbituric acid (TBA) dissolved in 75 mM potassium phosphate monobasic buffer at a pH of 2.5. As a standard control, 0.5 mL of MDA solution (20 μM) was incubated with 1 mL of TBA. Samples were maintained at 96°C for 45 min. After cooling the solution, 4 mL of n-butyl alcohol was added, followed by centrifugation at $2000 \times g$ for 15 min. The supernatants from the samples were analyzed at 532 nm. Two independent experiments were performed in duplicate. The MDA levels of the samples were expressed in nmol/mL and were obtained by the following formula: $\text{MDA (nmol/mL)} = \text{ABS}_{\text{sample}} \times (20 \times 220.32 \text{ ABS}_{\text{standardMDA}})$.

2.5. Antidiabetic properties

2.5.1. Alpha-glucosidase assay

The α -glucosidase assay was performed according to the method described by Kazeem et al. (2013) using α -glucosidase from *Saccharomyces cerevisiae*. The substrate solution *p*-nitrophenyl glucopyranoside (pNPG) was prepared in 20 mM phosphate buffer at a pH of 6.9. For this experiment, 10 μL of α -glucosidase (1.0 U/mL) was pre-incubated with 5 μL of the different concentrations of the extract (1–100 $\mu\text{g}/\text{mL}$) for 10 min. Then, 5 μL of 3.0 mM pNPG as a substrate dissolved in 20 mM phosphate buffer (pH = 6.9) was then added to start the reaction. The reaction mixture was incubated at 37°C for 20 min and stopped by adding 200 μL of 0.1 M Na_2CO_3 . The α -glucosidase activity was determined by measuring the yellow-colored paranitrophenol released from pNPG at 405 nm. A control was prepared using the same procedure but replacing the extract with distilled water. Two independent experiments were performed in triplicate. The results were expressed as a percentage of the blank control. The percentage inhibition is calculated as $\% \text{ Inhibition} = [(\text{Abs}_{\text{control}} - \text{Abs}_{\text{extract}}) / \text{Abs}_{\text{control}}] \times 100$. The IC_{50} values were determined.

2.5.2. Anti-glycation assay

The anti-glycation activity was evaluated according to the method described by Kiho et al. (2004). For this experiment, a solution of 0.1 mM fructose, 30 mM glyoxal and 8 mg/mL BSA was prepared in phosphate buffer (0.2 M, pH = 7.4, containing 3 mM sodium azide as an antimicrobial agent). Briefly, the 300 μL of reaction mixture was composed of BSA (135 μL), fructose or glyoxal (135 μL), and extract (30 μL). After this, the samples were incubated at 37°C for 48 h or 72 h (under sterile conditions). Then, each sample was examined for the development of fluorescence ($\lambda_{\text{ex}} = 330 \text{ nm}$ and $\lambda_{\text{em}} = 420 \text{ nm}$), against blank on a microtiter plate reader. Quercetin was used as the standard. A control was prepared using the same procedure but replacing the extract with distilled water. Three independent experiments were performed in triplicate. The percent inhibition of each extract was calculated by using the following formula: $\%$

$\text{inhibition} = (1 - \text{fluorescence}_{\text{sample}} / \text{fluorescence}_{\text{control}}) \times 100$. The IC_{50} values were determined.

2.6. In vivo studies

The experimental procedures with mice followed the standards of the CONCEA (Conselho Nacional de Controle de Experimentação Animal) and were approved by the CEUA/UFGD (Comissão de Ética para Uso de Animais/Universidade Federal da Grande Dourados; process number 37/2015). C57Bl/6 mice, 20–30 g and 16–24 weeks of age, were obtained from the UFGD Central Animal Facility, Mato Grosso do Sul (MS), Brazil. The mice were housed in microisolators (5 mice per microisolator) and kept under standard conditions (12 h light and 12 h dark, $22 \pm 2^\circ\text{C}$), with access to water and feed ad libitum. Before starting the experiment, the mice were acclimated to the laboratory conditions. The dose administered for in vivo assays was selected based on the acute toxicity study. The dose chosen was one tenth of the dose considered to be safe.

2.6.1. Acute toxicity

The acute toxicity test was performed based on the protocols of the Organization for Economic Cooperation and Development (OECD) Guideline 425. On the first day, one C57Bl/6 mouse, after an 8 h fasting period, received the dose of 2000 mg/kg MESL by gavage. Subsequently, four other mice were subjected to 8 h of fasting and to a single dose of 2000 mg/kg MESL. The same procedure was subsequently repeated in another group of mice using the dose of 5000 mg/kg MESL to define the lethal dose for 50% of the mice (LD_{50}). The mice were periodically observed during the first 24 h and then once daily for 14 d, with the body mass as well as water and food intake recorded. At the end of the observation period, all mice were euthanized. The organs (heart, lungs, liver and kidneys) were removed, weighed and macroscopically analyzed.

2.6.2. Glucose tolerance test

The glucose tolerance test (GTT) was performed according to the method described by Lanjhiyana et al. (2011). For this purpose, adult male C57Bl/6 mice were used. The mice fasted for 12 h and were divided into the following four groups of five mice each: (I) Control: water by gavage; (II) Glib: 10 mg/kg glibenclamide by gavage; (III) Met: 100 mg/kg metformin by gavage; and (IV) MESL: 200 mg/kg methanolic extract of the leaves of *S. terebinthifolius* by gavage. A glucose solution (2 g/kg) was administered by gavage to all mice. Blood samples were collected from the caudal vein at time 0 (immediately before glucose administration) and at 30, 60, 90, 120 and 180 min after glucose administration. Blood glucose levels were determined using the AccuChek® active blood glucose meter.

2.6.3. Induction of diabetes and experimental procedures

Diabetes was induced in C57Bl/6 mice fasted for 12 h by a single intraperitoneal injection of a 180 mg/kg alloxan monohydrate solution. The alloxan monohydrate solution was prepared with 0.9% NaCl. After 72 h, the serum glucose levels were determined using an AccuChek® active blood glucose meter. Mice with fasting glycemia higher than 200 mg/dL were considered diabetic.

The mice were divided into the following four groups of five animals: (I) ND-Control: normoglycemic mice treated with water; (II) D-Control: diabetic mice treated with water; (III) D-Met: diabetic mice treated with 100 mg/kg metformin; and (IV) D-MESL: diabetic mice treated with 200 mg/kg methanolic extract of leaves of *S. terebinthifolius*. The treatments were administered by gavage for 28 d once daily. After this period, the mice were euthanized, and the blood was collected to assess biochemical and hematological parameters. The organs (heart, liver and kidneys) were removed and weighed to calculate the relative mass (g of organ per 100 g of body weight).

Table 1
Microbiological evaluations (CFU/g) of the powders and the methanolic extracts of roots, stem bark and leaves from *Schinus terebinthifolius* Raddi.

	Powder			Extract		
	root	stem bark	leaves	root	stem bark	leaves
Mesophilic microorganisms	$1.90 \times 10^{-3} \pm 0.001$	$1.43 \times 10^0 \pm 0.11$	$5.17 \times 10^{-1} \pm 0.01$	absent	absent	absent
Psychrophyle microorganisms	$4.70 \times 10^0 \pm 1.54$	$4.73 \times 10^1 \pm 7.70$	absent	absent	absent	absent
Molds and yeasts	$1.93 \times 10^1 \pm 1.85$	$4.95 \times 10^1 \pm 7.70$	absent	absent	absent	absent
<i>Clostridium</i> sulfite reducer	absent	absent	absent	absent	absent	absent
<i>Salmonella</i> sp.	absent	absent	absent	absent	absent	absent
<i>Escherichia coli</i>	absent	absent	absent	absent	absent	absent
<i>Staphylococcus aureus</i>	absent	absent	absent	absent	absent	absent
<i>Bacillus cereus</i>	$1.87 \times 10^1 \pm 7.21$	absent	absent	absent	absent	absent

The results are expressed as the mean \pm SEM.

2.7. Statistical analysis

The data are expressed as the mean \pm standard error of the mean (SEM). Analysis of variance (ANOVA) with the Student Newman Keuls post-test was used for analysis and comparison between the experimental groups. The area under the curve (AUC) was used for the GTT. All statistical tests were performed using the software GraphPad Prism, version 5.0. Data were considered significant when $P < 0.05$.

3. Results

3.1. Microbiological quality

Table 1 presents the microbiological evaluation of the powders and MESR, MESB and MESL of *S. terebinthifolius*. The growth of mesophilic microorganisms was observed in the powders of roots, stem bark and leaves of *S. terebinthifolius*. Colonies of psychrophilic microorganisms, molds and yeasts grew in the powders of roots and stem bark. No growth of pathogenic microorganisms was observed, except in root powder, where *Bacillus cereus* colonies grew. However, no microbial growth occurred in the MESR, MESB and MESL of *S. terebinthifolius*.

3.2. Chemical constituents

Table 2 presents the contents of lipophilic and hydrophilic compounds of the MESR, MESB and MESL. The hydrophilic compounds stood out in all extracts, particularly phenolic compounds, which were the main components. The MESB and MESL had the highest concentrations of phenolic acids and flavonoids.

3.3. Antioxidant activity

The antioxidant activities of the MESR, MESB and MESL were observed in the DPPH \cdot , ABTS \cdot^+ , FRAP, reducing power, β -carotene bleaching (Table 3) and MDA assays in human erythrocytes (Fig. 1).

Regarding the controls used, the IC₅₀ DPPH \cdot and ABTS \cdot^+ concentrations of the extracts were similar to those of ascorbic acid and

lower than those of BHT (Table 3). The EC₅₀ values of the MESL in the FRAP and reducing power assays were lower than those of the MESR and MESB as well as approximately twice as high as those of ascorbic acid (Table 3).

In the β -carotene bleaching assay (Table 3), the MESL had a lower IC₅₀ than the other extracts and (approximately 18 times) a higher IC₅₀ than the antioxidant BHA. The IC₅₀ of ascorbic acid was not detected in this assay.

In human erythrocytes, the extracts reduced the oxidative stress induced by the oxidant agent AAPH, as shown by the lower levels of MDA generated (Fig. 1). At the concentrations tested (50 to 125 μ g/mL), the MESL promoted lower levels of MDA than the other extracts and the control, ascorbic acid (Fig. 1).

3.4. In vitro antidiabetic properties

The antidiabetic properties of the MESR, MESB and MESL were determined *in vitro* by the inhibition of the activity of the digestive enzyme α -glucosidase and by the anti-glycation effect *via* fructose as well as glyoxal (Table 4).

S. terebinthifolius extracts inhibited the activity of the enzyme α -glucosidase, and the MESL showed a higher activity than the other extracts, with an IC₅₀ approximately twice as low as that of the other extracts (Table 4). The MESL showed higher anti-glycation activity than the other extracts, and the control quercetin had an IC₅₀ (approximately 4 times) higher than fructose and similar to that of glyoxal (Table 4).

3.5. Chemical profile of the MESL

The chemical constituents were identified by their UV spectra, accurate mass and fragment ions compared to published data in the literature, and some metabolites were confirmed by the injection of authentic standards.

The identified constituents were *O*-glycosylated flavonols 4–7, 9–10, 12–14, 16–17, and 19–20; gallotannins 3, 8, 15, and 18; and gallic acid 1 along with its derivatives 2 and 11 (Fig. 2, Table 5). The main compounds observed in the chromatogram ($\lambda = 270$ –330 nm) were 4-*O*-

Table 2
Lipophilic and hydrophilic compounds of the methanolic extracts of roots (MESR), stem bark (MESB) and leaves (MESL) from *Schinus terebinthifolius* Raddi.

Compounds	MESR	MESB	MESL
Lipophilic			
β -Carotene (mg/g extract)	0.054 ± 0.006^a	0.313 ± 0.027^b	1.455 ± 0.009^c
Lycopene (mg/g extract)	0.029 ± 0.002^a	0.049 ± 0.008^b	0.013 ± 0.002^a
Hydrophilic			
Ascorbic acid (mg/g extract)	0.115 ± 0.002^a	0.123 ± 0.002^a	0.070 ± 0.003^b
Phenolics (mg GAE/g extract)	300.42 ± 9.30^a	274.94 ± 8.09^a	446.48 ± 28.93^b
Phenolic acids (mg CAE/g extract)	24.49 ± 1.80^a	49.12 ± 1.30^b	52.95 ± 4.23^b
Flavonoids (mg QE/g extract)	21.16 ± 2.65^a	55.72 ± 1.56^b	57.78 ± 3.79^b

The results are expressed as the mean \pm SEM.

Table 3Antioxidant activities of the methanolic extract of root (MESR), stem bark (MESB) and leaves (MESL) from *Schinus terebinthifolius* Raddi.

Sample	DPPH·	ABTS· ⁺	FRAP	Reducing power	β-carotene bleaching
	IC ₅₀ (μg/mL)		EC ₅₀ (μg/mL)		IC ₅₀ (μg/mL)
Ascorbic acid	3.06 ± 0.16	2.31 ± 0.05	33.58 ± 0.80	42.97 ± 0.70	ND
Lipophilic antioxidant	37.45 ± 3.09	20.87 ± 1.82	–	–	3.80 ± 0.10
MESR	6.31 ± 0.06	3.25 ± 0.22	85.11 ± 4.27	133.52 ± 1.11	176.56 ± 21.30
MESB	4.50 ± 0.11	4.45 ± 0.49	116.33 ± 3.53	169.76 ± 1.90	220.37 ± 35.99
MESL	4.17 ± 0.69	3.83 ± 0.36	68.78 ± 2.01	95.30 ± 3.64	67.06 ± 3.78

Lipophilic antioxidant: BHT for DPPH· and ABTS·⁺; BHA for the β-carotene bleaching assay. ND: not detected. -: unrealized. The results are expressed as the mean ± SEM.

methyl gallic acid 2 and penta-*O*-galloyl hexoside 15 (Fig. 2).

The peaks 1, 2 and 11 showed a $\lambda_{\max} \approx 280$ nm, and gallic acid (1) was confirmed by a standard. Compound 2 exhibited intense ions at m/z 185.0451 [M + H]⁺ and 183.0304 [M-H]⁻, confirming the molecular formula C₈H₈O₅ and an additional methyl on the gallic acid. The fragment ion at m/z 153.0186 (C₇H₅O₄⁺, error = 2.4 ppm) indicated the loss of a methanol molecule (32 *u*), which is a diagnostic ion for a methyl group at C-4 (Liao et al., 2013) because the losses of radical methyl and, subsequently, CO₂ molecules suggest a methyl substituent at C-3 or C-7 (carboxyl) (Kumar et al., 2015; Ersan et al., 2016). For compound 11, the ion m/z 335.0412 [M-H]⁻ (C₁₅H₁₁O₉⁻, error = 2.8 ppm) yielded the fragment ion at m/z 183 by the loss of a galloyl unit, which is relative to a methylated galloyl, as reported by Ersan et al. (2016). Thus, compounds 1, 2 and 11 were identified as gallic acid, 4-*O*-methyl gallic acid and methyl digallate, respectively.

The substances 3, 8, 15 and 18 showed absorption bands with a λ_{\max} similar to gallic acid. In addition, they revealed consecutive losses of galloyl units (152 *u*) and/or losses of a galloyl unit and subsequently a water molecule (170 *u*). They also showed the typical fragment ion at m/z 169 [gallic acid-H]⁻ and the absence of an ion at m/z 301, which confirmed the identification of gallotannins (Ersan et al., 2016; Muccilli et al., 2017). For example, compound 15 exhibited an intense ion at m/z 939.1102 [M-H]⁻ (compatible with C₄₁H₃₁O₂₆⁻) and yielded fragment ions by the losses of galloyl units such as m/z 787 [M-H-galloyl]⁻, 769 [M-H-galloyl-H₂O]⁻, 617 [M-H-2 × galloyl-H₂O]⁻, 599 [M-H- 2 × galloyl-2 × H₂O]⁻, 447 [M-H-3 × galloyl-2 × H₂O]⁻, and 277 [M-H- 4 × galloyl-3 × H₂O]⁻; thus, they confirmed the identification of penta-*O*-galloyl hexoside, a compound already described for *S. terebinthifolius* (Hayashi et al., 1989). Additionally, the substances 3, 8 and 18 were identified as tri-*O*-galloyl hexoside, tetra-*O*-galloyl hexoside and hexa-*O*-galloyl hexoside, respectively. All data agreed with the published data for these compounds (Abu-Reidah et al., 2015; Kumar et al., 2015; Ersan et al., 2016; Muccilli et al., 2017).

Compounds 4–7, 9–10, 12–14, 16–17 and 19–20 revealed UV

Table 4α-Glucosidase inhibition and anti-glycation activity by the methanolic extracts of the roots (MESR), stem bark (MESB) and leaves (MESL) from *Schinus terebinthifolius* Raddi.

Sample	α-Glucosidase IC ₅₀ (μg/mL)	Anti-glycation	
		Fructose IC ₅₀ (μg/mL)	Glyoxal IC ₅₀ (μg/mL)
Quercetin	–	0.32 ± 0.01	35.12 ± 0.27
MESR	31.16 ± 0.17	3.16 ± 0.01	116.18 ± 2.23
MESB	33.01 ± 1.65	1.54 ± 0.03	98.43 ± 0.48
MESL	16.13 ± 0.49	1.29 ± 0.01	32.40 ± 0.84

The results are expressed as the mean ± SEM.

spectra similar to flavonol ($\lambda_{\max} \approx 265$ and 350 nm) (Ersan et al., 2016). The substances 4–7, 9 and 19 yielded a main fragment ion at m/z 316, while compounds 10, 12, and 16 as well as 14, 17, and 20 yielded fragment ions at m/z 284 and 300 in negative ion mode, which are compatible with the aglycones myricetin (C₁₅H₈O₈⁻), quercetin (C₁₅H₈O₇⁻) and kaempferol (C₁₅H₈O₆⁻). The losses of 132, 146 and 162 *u* confirmed the sugars pentosyl, deoxyhexosyl and hexosyl, respectively. All of the fragment ions were similar to data reported in the literature (March et al., 2006; Liao et al., 2013; Ersan et al., 2016).

3.6. Acute toxicity

Table 6 presents the anthropometric parameters of mice treated with the MESL in the acute toxicity test. No mortality was observed during the experimental period after administering doses of 2000 and 5000 mg/kg MESL. The mice treated with 2000 mg/kg MESL showed no changes in the anthropometric parameters (Table 6). However, the mice treated with 5000 mg/kg MESL showed decreased body mass, increased water and feed intake and a slight decrease in kidney weight




Fig. 1. Antioxidant activities of the methanolic extracts of the roots (MESR), stem bark (MESB) and leaves (MESL) from *Schinus terebinthifolius* Raddi in human erythrocytes with AAPH-induced oxidative stress. MDA: malondialdehyde. The values shown are the mean ± SEM. ****P* < 0.001 versus the control (NaCl 0.9%).




Fig. 2. Chromatographic profile at 270–330 nm of the methanolic extract of *Schinus terebinthifolius* Raddi leaves (MESL).

when compared with the other groups. Thus, considering the data together, the LD₅₀ of the MESL was estimated as higher than 5000 mg/kg, and the *in vivo* assays proceeded with a dose of 200 mg/kg, that is, 10 times lower than the dose considered safe in this study.

3.7. *In vivo* antidiabetic properties

3.7.1. Oral glucose tolerance test

Fig. 3 shows the effects of the MESL on the glycemia of normoglycemic mice after oral glucose overload. The MESL reduced the glycemic peak at 30 min by $35 \pm 5\%$ (Fig. 3A) as well as the postprandial glycemia by $24 \pm 6\%$, as assessed by the AUC up to 180 min (Fig. 3B) when compared with the control group. Furthermore, the effects of the MESL on the glycemia of normoglycemic mice were similar to those

induced by glibenclamide and weaker than those of metformin.

3.7.2. *In vivo* antidiabetic activity

Table 7 presents the anthropometric and biochemical parameters of normoglycemic (ND-Control) and diabetic C57Bl/6 mice treated with water (D-Control), metformin (D-Met) and the MESL (D-MESL). The evolution of the glycemic parameters of all the experimental groups are represented in Table S1.

Diabetic mice (D-Control) showed higher water and feed intake, glycemia, glycosylated hemoglobin, AST and ALT liver enzymes and liver weight than the ND-Control group (Table 7). Diabetic mice treated with the MESL (D-MESL) showed decreased water intake, and the other anthropometric and biochemical parameters were normal (Table 7). In all experimental groups, the organs (liver, kidneys, heart and pancreas)

Table 5

Identification of the constituents from the MESL of *Schinus terebinthifolius* by LC-DAD-MS/MS.

Peak	RT (min)	Compound	UV (nm)	FM	Negative mode <i>m/z</i>		Positive mode <i>m/z</i>	
					MS [M-H] ⁻ (ppm ^{err})	MS/MS	MS [M + H] ⁺ (ppm ^{err})	MS/MS
1	2.4	Gallic acid*	270	C ₇ H ₆ O ₅	169.0146 (2.1)	–	171.0295 (4.0)	–
2	8.2	4- <i>O</i> -methyl gallic acid	271	C ₈ H ₈ O ₅	183.0304 (2.8)	–	185.0451 (3.6)	153
3	19.5	Tri- <i>O</i> -galloyl hexoside	278	C ₂₇ H ₂₄ O ₁₈	635.0873 (2.7)	465, 313, 169	659.0883 ^{Na} (4.3)	153
4	21.4	Myricetin <i>O</i> -hexoside	265, 365	C ₂₁ H ₂₀ O ₁₃	479.0819 (2.6)	316	481.0993 (3.3)	319
5	21.6	Myricetin <i>O</i> -hexosyl-deoxyhexoside	265, 355	C ₂₇ H ₃₀ O ₁₇	625.1396 (2.3)	479, 316	627.1564 (1.3)	481, 319
6	21.8	Myricetin <i>O</i> -hexosyl-deoxyhexoside	265, 355	C ₂₇ H ₃₀ O ₁₇	625.1416 (1.0)	479, 316	627.1585 (4.6)	481, 319
7	22.3	Myricetin <i>O</i> -pentoside	265, 353	C ₂₀ H ₁₈ O ₁₂	449.0721 (1.0)	316	451.0888 (3.7)	319, 273, 245, 167
8	23.2	Tetra- <i>O</i> -galloyl hexoside	278	C ₃₄ H ₂₈ O ₂₂	787.1000 (0.1)	635, 617, 465, 169	811.0966 ^{Na} (0.2)	–
9	23.5	Myricetin <i>O</i> -deoxyhexoside	265, 350	C ₂₁ H ₂₀ O ₁₂	463.0882 (1.3)	316, 271	465.1048 (4.3)	319, 245, 217, 153
10	23.8	Quercetin <i>O</i> -hexoside	265, 353	C ₂₁ H ₂₀ O ₁₂	463.0881 (0.2)	300	465.1044 (3.6)	303
11	24.4	Methyl digallate	275	C ₁₅ H ₁₂ O ₉	335.0412 (1.1)	183	337.0568 (4.2)	153
12	25.1	Quercetin <i>O</i> -pentoside	263, 355	C ₂₀ H ₁₈ O ₁₁	433.0775 (0.4)	300, 271	435.0911 (2.5)	303
13	25.5	Quercetin <i>O</i> -pentoside	263, 355	C ₂₀ H ₁₈ O ₁₁	433.0772 (0.9)	300, 271	435.0938 (3.7)	303
14	25.6	Kaempferol <i>O</i> -hexoside	263, 350	C ₂₁ H ₂₀ O ₁₁	447.0950 (3.9)	284	449.1086 (1.8)	287
15	25.7	Penta- <i>O</i> -galloyl hexoside	279	C ₄₁ H ₃₂ O ₂₆	939.1102 (0.8)	787, 769, 617, 599, 447, 277, 169, 125	963.1107 ^{Na} (3.4)	793, 641, 471, 301, 153
16	26.5	Quercetin <i>O</i> -deoxyhexoside	260, 350	C ₂₁ H ₂₀ O ₁₁	447.0943 (2.2)	300, 271, 255	449.1070 (1.9)	303
17	27.1	Kaempferol <i>O</i> -pentoside	263, 350	C ₂₀ H ₁₈ O ₉	417.2125 (1.3)	284	419.0991 (4.5)	287
18	27.9	Hexa- <i>O</i> -galloyl hexoside	280	C ₄₈ H ₃₆ O ₃₀	1091.1212 (0.6)	921, 769, 617, 393	1115.1175 ^{Na} (0.7)	–
19	28.5	Myricetin <i>O</i> -galloyl <i>O</i> -deoxyhexoside	267, 280, 350	C ₂₈ H ₂₄ O ₁₆	615.1003 (1.9)	317	617.1145 (1.2)	–
20	28.9	Kaempferol <i>O</i> -deoxyhexoside	263, 350	C ₂₁ H ₂₀ O ₁₀	431.0989 (1.1)	284	433.1121 (2.0)	287
21	64.0	Unknown	300	C ₂₄ H ₃₆ O ₃	371.2581 (2.8)	327	373.2747 (2.7)	355

(ppm^{err}): Error in ppm; ^{Na}: [M + Na]⁺; *: confirmed by an authentic standard.

Table 6

Anthropometric parameters of C57Bl/6 normal mice in the acute toxicity test treated with the methanolic extract of leaves from *Schinus terebinthifolius* Raddi (MESL).

Anthropometric parameters	Control	MESL	
		2000 mg/kg	5000 mg/kg
Δ BW (%)	−0.31 ± 1.30 ^a	−2.78 ± 1.62 ^{ab}	−5.73 ± 1.11 ^b
Water intake (mL/day)	6.25 ± 0.45 ^a	6.02 ± 0.52 ^a	12.36 ± 0.77 ^b
Food intake (g/day)	3.84 ± 0.21 ^a	5.14 ± 0.31 ^{ab}	6.30 ± 0.65 ^b
Liver (g/100 g of BW)	3.93 ± 0.10	3.59 ± 0.09	3.75 ± 0.14
Lung (g/100 g of BW)	0.60 ± 0.02	0.68 ± 0.09	0.62 ± 0.02
Kidney (g/100 g of BW)	1.06 ± 0.02 ^{ab}	1.11 ± 0.06 ^a	0.95 ± 0.02 ^b
Heart (g/100 g of BW)	0.56 ± 0.03	0.57 ± 0.04	0.54 ± 0.02

Δ BW (%): variation in the % between the final and initial body weight. The values shown are the mean ± SEM. *N* = 5 mice per group. Different letters indicate statistically significant differences.

were evaluated macroscopically and no presented changes in respect to their color, consistency, size or presence of lesions e tumors. The effects of the MESL on the parameters assessed in diabetic mice were stronger than those triggered by the reference drug metformin at the concentrations tested (Table 7).

4. Discussion

Scientific knowledge about the biological activities of medicinal plants may stimulate the development of new therapeutic alternatives. *Schinus terebinthifolius* Raddi is a medicinal plant commonly used for various purposes, and it is included in the list of medicinal plants indicated by the Brazilian public health system (RENISUS, 2009).

Natural products are subjected to microbiological and toxicological assessments to determine their safety. The presence of microorganisms in plants results from different soil, air and water contaminants. Many of these contaminants in non-sterile pharmaceuticals can alter their therapeutic properties and damage health (Ratajczak et al., 2015). The presence of the pathogenic microorganism *Bacillus cereus* exclusively in the *S. terebinthifolius* root powder and the absence of microbial growth in the extracts of all plant parts may indicate the microbiological safety of these plant materials, characterizing them as high-quality natural products (Santos et al., 2018). Furthermore, the absence of toxicity signs in the acute toxicity test supports the pharmacological potential of *S. terebinthifolius*.

Plant extracts have a set of different bioactive constituents, and

phenolic compounds were the major constituents hydrophilic of the *S. terebinthifolius* extracts. However, different parts of the same plant may have different composition of phytochemical constituents (Singh et al., 2015). Among the extracts, the MESL had the highest content of phenolic compounds and β-Carotene (lipophilic compound) as well as the highest efficacy for the biological activities tested. Phenolic compounds are known to act as antioxidants, especially for their ability to donate hydrogen or electrons, thereby inhibiting the action of reactive oxygen species (ROS) and lipid peroxidation reactions (Rice-Evans et al., 1997).

The free radical scavenging observed in this study indicates the potential of these extracts to donate electrons to stabilize radical molecules. This ability is crucial because the excess of free radicals is one of the main factors that causes and worsens pathological conditions such as cancer (Reuter et al., 2010), obesity (Fernandez-Sanchez et al., 2011), cardiovascular diseases (Csányi and Miller, 2014) and diabetes (Giacco and Brownlee, 2010).

The hydroxyl radical (OH·) is one of the most reactive molecules for which no endogenous defense system is available (Lipinski, 2011). OH· is formed in Fenton's reaction, in which ferrous iron (Fe²⁺) is oxidized to ferric iron (Fe³⁺) by hydrogen peroxide (H₂O₂) (Winterbourn, 1995). *S. terebinthifolius* extracts showed a lower iron reducing power than the ascorbic acid standard, and therefore, they can avoid OH· generation. Some antioxidants with a high iron reducing power may have pro-oxidant characteristics (Chobot and Hadacek, 2011).

In biological systems, membrane lipids are targets of OH·, which is able to oxidize polyunsaturated fatty acids and form lipid hydroperoxides (Ayala et al., 2014). The inhibition of the oxidation of the lipid substrate β-carotene by *S. terebinthifolius* extracts may indicate the ability to prevent changes in membrane structure and permeability resulting from lipid peroxidation.

Those membrane changes may result from the toxic byproducts of lipid peroxidation, such as MDA (Grotto et al., 2009). In human erythrocytes under induced oxidative stress, *S. terebinthifolius* extracts reduced the MDA levels generated, with the MESL showing the highest effect.

Oxidative stress affects virtually all physiological systems and is associated with the development of various diseases, including diabetes (Giacco and Brownlee, 2010). Increased glycemia also increases free radical production, primarily through protein glycation (Singh et al., 2014). Glycated hemoglobin and fructosamine are examples of Amadori products that form AGEs (Gillery, 2014). The formation of AGEs is closely related to the development of diabetic complications (Node and Inoue, 2009; Singh et al., 2014); therefore, glycemic control is critical to prevent such events (Skyler, 2004). The binding of AGEs to their




Fig. 3. (A) Glycemia and (B) AUC obtained in the glucose tolerance test in C57Bl/6 normoglycemic mice that received a single oral dose of the following: water (Control), glibenclamide (Glib), 100 mg/kg metformin (Met) and the methanolic extract of leaves from *Schinus terebinthifolius* Raddi at 200 mg/kg (MESL). Values shown are the mean ± SEM. *N* = 5 mice per group. Different letters indicate statistically significant differences.

Table 7

Anthropometric and biochemical parameters of C57Bl/6 normoglycemic (ND-Control) and diabetic mice treated during 28 days with water (D-Control), 100 mg/kg metformin (D-Met) and the methanolic extract of leaves from *Schinus terebinthifolius* Raddi at 200 mg/kg (D-MESL).

Parameters	Normal	Diabetic		
	ND-Control	D-Control	D-Met	D-MESL
Anthropometric				
Δ BW (%)	5.71 ± 2.43	0.43 ± 4.21	7.95 ± 3.12	8.60 ± 2.05
Water intake (mL/day)	7.51 ± 0.38 ^a	30.41 ± 1.49 ^b	23.32 ± 1.15 ^c	11.23 ± 0.76 ^d
Food intake (g/day)	4.55 ± 0.24 ^a	6.79 ± 0.47 ^b	6.51 ± 0.17 ^b	4.81 ± 0.23 ^a
Liver (g/100 g of BW)	4.14 ± 0.15 ^{ac}	5.21 ± 0.15 ^b	4.69 ± 0.20 ^{ab}	4.02 ± 0.17 ^c
Kidney (g/100 g of BW)	1.08 ± 0.03	1.48 ± 0.05	1.12 ± 0.09	1.03 ± 0.03
Heart (g/100 g of BW)	0.45 ± 0.01	0.46 ± 0.01	0.45 ± 0.01	0.49 ± 0.03
Pancreas (g/100 g of BW)	0.27 ± 0.06	0.16 ± 0.06	0.20 ± 0.06	0.21 ± 0.03
Biochemical				
Glycemia (mg/dL)	134.40 ± 6.39 ^a	481.25 ± 14.57 ^b	288.00 ± 74.69 ^c	160.33 ± 22.00 ^a
HbA1c (%)	4.82 ± 0.02 ^a	9.13 ± 0.48 ^b	6.74 ± 1.26 ^{ab}	6.05 ± 0.61 ^a
Total cholesterol (mg/dL)	99.74 ± 6.90	105.55 ± 7.98	95.44 ± 6.41	108.73 ± 1.57
HDL-cholesterol (mg/dL)	102.72 ± 8.41	107.90 ± 7.68	91.24 ± 6.35	106.92 ± 2.17
Triglyceride (mg/dL)	50.80 ± 4.13	48.90 ± 5.36	56.36 ± 6.32	66.27 ± 5.63
AST (U/L)	63.54 ± 6.15 ^a	163.08 ± 20.04 ^b	77.84 ± 13.06 ^a	61.23 ± 7.98 ^a
ALT (U/L)	26.32 ± 2.58 ^a	71.98 ± 15.29 ^b	35.20 ± 4.61 ^a	30.48 ± 4.01 ^a
Urea (mg/dL)	106.34 ± 8.86	143.25 ± 20.51	112.82 ± 12.72	105.55 ± 8.37
Creatinine (mg/dL)	0.23 ± 0.02	0.27 ± 0.02	0.25 ± 0.02	0.23 ± 0.01

ΔBW (%): variation in the % between the final and initial body mass; HbA1c: glycated hemoglobin; AST: aspartate transaminase; ALT: alanine transaminase. The values shown are the mean ± SEM. N = 5 mice per group. Different letters indicate statistically significant differences.

receptors (RAGEs) leads to cellular dysfunction, which includes the increased production of inflammatory cytokines, such as interleukin 1 and 6 (IL-1 and IL-6), growth factor I (GF-1) and tumor necrosis factor alpha (TNFα) (Singh et al., 2014). AGEs accumulate in most target organs of diabetes, such as the kidneys and retina (Singh et al., 2014). The anti-glycation activity of the extracts was shown by the decreased glycation *via* fructose and glyoxal, and the MESL had a higher anti-glycation activity than the other extracts. Diabetic animals treated with the MESL showed reduced levels of glycated hemoglobin.

Oxidative stress, hyperglycemia and diabetes control have been related to the action of various natural substances, particularly phenolic compounds (Rice-Evans et al., 1997; Xie and Chen, 2013). Gallic acid and its derivatives, gallotannins and glycosylated flavonols of myricetin, quercetin and kaempferol were identified in the MESL. In other studies, these phenolic compounds have been related to antioxidant action and glycemic control. Gallic acid and its derivatives have been described as oxidative stress reducers (Abdel-Moneim et al., 2017; Karimi-Khouzani et al., 2017; Omobowale et al., 2017). Tannins have antioxidant properties, although they primarily maintain glycemic levels by inhibiting α-glucosidase (Lee et al., 2017; Muccilli et al., 2017). Studies indicate the effect of glycosylated quercetin on glycemic reduction by protecting pancreatic cells or improving insulin sensitivity (Yan et al., 2015). Decreased fasting glycemia and the serum levels of glycated hemoglobin have already been observed *in vivo* after the administration of glycosylated kaempferol (Zang et al., 2015). Other studies observed that glycosylated flavonols are also capable of inhibiting α-glucosidase activity (Sun et al., 2014) and glycosylating proteins *in vitro* (Kim et al., 2004). In addition to the above effects, the MESL reduced postprandial glycemia in normoglycemic mice after glucose overload, thus indicating their ability to change mechanisms of glycemic control.

The mechanisms currently used to control hyperglycemia include the inhibition of the activity of the digestive enzyme α-glucosidase, which regulates the uptake of glucose generated from starch (van de Laar, 2008). Glucosidase inhibitors, such as acarbose, miglitol and voglibose, act as enzymatic α-glucosidase antagonists, reducing intestinal glucose uptake and postprandial glycemia, albeit causing side effects such as flatulence, diarrhea and abdominal pain (van de Laar et al., 2005). *S. terebinthifolius* extracts, especially the MESL, inhibited α-glucosidase activity, and the inhibition of this enzyme has been a promising target for the development of antidiabetic drugs (van de Laar,

2008).

The classic symptoms of chronic hyperglycemia, polydipsia and polyphagia, which reflect homeostatic imbalances in diabetes (Fournier, 2000; American Diabetes Association, 2009), were partly or fully reversed with the administration of the MESL to diabetic mice. Feed intake normalization in diabetic mice treated with the MESL correlates positively with the decrease in glucose and glycated hemoglobin levels observed in these animals.

Similarly, hepatomegaly as well as the elevated AST and ALT levels of diabetic mice, likely related to the excessive glycogen accumulation in hepatocytes (Sarkhy et al., 2017), were fully reversed in diabetic mice treated with the MESL, which showed normalization of the liver weight as well as the liver enzymes AST and ALT, similarly to mice treated with metformin.

Overall, the data showed that *S. terebinthifolius* extracts are micro-biologically safe and these extracts, particularly the MESL, help control oxidative stress, postprandial hyperglycemia and the main symptoms of diabetes. This action is most likely mediated by their chemical constituents, such as gallic acid, gallotannins and glycosylated flavonols.

Declaration of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.cbpc.2019.02.007>.

Acknowledgements

This work was supported by grants from Foundation to Support to Fundação de Apoio ao Desenvolvimento do Ensino, Ciência e Tecnologia do Estado de Mato Grosso do Sul (FUNDECT), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).

References

- Abdel-Moneim, A., Yousef, A.I., Abd El-Twab, S.M., Abdel Reheim, E.S., Ashour, M.B., 2017. Gallic acid and p-coumaric acid attenuate type 2 diabetes-induced neurodegeneration in rats. *Metab. Brain Dis.* 32, 1279–1286. <https://doi.org/10.1007/>

- 01018-2.
- Rocha, P.S., Campos, J.F., Nunes-Souza, V., Vieira, M.C., Boleti, A.P.A., Rabelo, L.A., Santos, E.L., de Pícoli Souza, K., 2017. Antioxidant and protective effects of *Schinus terebinthifolius* Raddi against doxorubicin-induced toxicity. *Appl. Biochem. Biotechnol.* 184, 869–884. <https://doi.org/10.1007/s12010-017-2589-y>.
- Santos, U.P.S., Tolentino, G.S., Morais, J.S., Souza, K.P., Estevinho, M.L.M.F., Santos, E.L., 2018. Physicochemical characterization, microbiological quality and safety, and pharmacological potential of *Hancornia speciosa* Gomes. *Oxidative Med. Cell. Longev.* 2018, 2976985. <https://doi.org/10.1155/2018/2976985>.
- Sarkhy, A.A.A., Zaidi, Z.A., Babiker, A.M., 2017. Glycogenic hepatopathy, an under-diagnosed cause of relapsing hepatitis in uncontrolled type 1 diabetes mellitus. *Saudi Med. J.* 38, 89–92. <https://doi.org/10.15537/smj.2017.1.15934>.
- Silva, J.H.S., Simas, N.K., Alviano, C.S., Alviano, D.S., Ventura, J.A., Lima, E.J., Seabra, S.H., Kuster, R.M., 2017a. Anti-*Escherichia coli* activity of extracts from *Schinus terebinthifolius* fruits and leaves. *Nat. Prod. Res.* 3, 1–4. <https://doi.org/10.1080/14786419.2017.1344657>.
- Silva, M.M., Iriguchi, E.K.K., Kassuya, C.A.L., Vieira, M.C., Foglio, M.A., Carvalho, J.E., Ruiz, A.L.T.G., Souza, K.P., Formagio, A.S.N., 2017b. *Schinus terebinthifolius*: phenolic constituents and in vitro antioxidant, antiproliferative and in vivo anti-inflammatory activities. *Rev. Bras.* 27, 445–452. <https://doi.org/10.1016/j.bjp.2016.12.007>.
- Singh, V.P., Bali, A., Singh, N., Jaggi, A.S., 2014. Advanced glycation end products and diabetic complications. *Kor. J. Physiol. Pharmacol.* 18, 01–14. <https://doi.org/10.4196/kjpp.2014.18.1.1>.
- Singh, A., Bajpai, V., Srivastava, M., Arya, K.R., Kumar, B., 2015. Rapid screening and distribution of bioactive compounds in different parts of *Berberis petiolaris* using direct analysis in real time mass spectrometry. *J. Pharm. Anal.* 5, 332–335. <https://doi.org/10.1016/j.jpha.2015.05.002>.
- Skyler, J.S., 2004. Effects of glycemic control on diabetes complications and on the prevention of diabetes. *Clin. Diab.* 22, 162–166. <https://doi.org/10.2337/diaclin.22.4.162>.
- Sun, J., Zhang, F., Yang, M., Zhang, J., Chen, L., Zhan, R., Li, L., Chen, Y., 2014. Isolation of α -glucosidase inhibitors including a new flavonol glycoside from *Dendrobium devonianum*. *Nat. Prod. Res.* 28, 1900–1905. <https://doi.org/10.1080/14786419.2014.955495>.
- Taga, M.S., Miller, E.E., Pratt, D.E., 1984. Chia seeds as a source of natural lipid antioxidants. *J. Am. Oil Chem. Soc.* 61, 928–931. <https://link.springer.com/article/10.1007/BF02542169>.
- Wild, S., Roglic, G., Green, A., Sicree, R., King, H., 2004. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. *Diabetes Care* 27, 1047–1053. [15111519](https://doi.org/10.2337.15111519).
- Winterbourn, C.C., 1995. Toxicity of iron and hydrogen peroxide: the Fenton reaction. *Toxicol. Lett.* 82, 969–974. [https://doi.org/10.1016/0378-4274\(95\)03532-X](https://doi.org/10.1016/0378-4274(95)03532-X).
- Xie, Y., Chen, X., 2013. Structures required of polyphenols for inhibiting advanced glycation end products formation. *Curr. Drug Metab.* 14, 414–431. <https://doi.org/10.2174/1389200211314040005>.
- Yan, S.X., Li, X., Sun, C.D., Chen, K.S., 2015. Hypoglycemic and hypolipidemic effects of quercetin and its glycosides. *Zhongguo Zhong Yao Za Zhi* 40, 4560–4567 (27141664).
- Zang, Y., Zhang, L., Igarashi, K., Yu, C., 2015. The anti-obesity and anti-diabetic effects of kaempferol glycosides from unripe soybean leaves in high-fat-diet mice. *Food Funct.* 6, 834–841. <https://doi.org/10.1039/c4fo00844h>.